Wolverine Trading
SLNO

Wolverine Trading’s Soleno Therapeutics SLNO Stock Holding History

Wolverine Trading’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$839K Buy
12,311
+5,235
+74% +$388K ﹤0.01% 3085
2025
Q2 		$589K Buy
+7,076
New +$530K ﹤0.01% 2798
2021
Q2 		– Sell
-1,698
Closed -$28.7K – 6629
2021
Q1 		$32K Buy
+1,698
New +$54.7K ﹤0.01% 5724

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wolverine Trading's SLNO Position: Q3 2025 in Review

Wolverine Trading increased its Soleno Therapeutics (SLNO) stake by 74% in Q3 2025, buying an estimated $388K and bringing the position to 12,311 shares worth $839K. The position accounts for ﹤0.01% of the portfolio, ranked #3085.

Wolverine Trading first reported a position in SLNO in Q1 2021 and has held it in 3 quarters since. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Wolverine Trading held 12,311 shares of Soleno Therapeutics worth $839K as of Q3 2025.
  • Wolverine Trading bought 5,235 Soleno Therapeutics shares in Q3 2025, an estimated $388K.
  • Soleno Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #3085 holding.
  • Wolverine Trading first reported a position in Soleno Therapeutics in Q1 2021 and has held it in 3 quarters since.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.